FDA Approves Dextenza for Treatment of Postoperative Ocular Pain

The US Food and Drug Administration has approved the first intracanalicular insert that delivers dexamethasone (Dextenza, Ocular Therapeutix) to treat ocular pain following ophthalmic surgery, the company has announced.

Dextenza, inserted in the lower lacrimal punctum and canaliculus, releases 0.4 mg dexamethasone for up to 30 days following insertion. Dextenza is resorbable and does not need to be removed. Saline irrigation or manual expression can be performed to remove the insert if necessary.

For more information: https://www.medscape.com

Related Articles

Share on facebook
Share on whatsapp
Share on email